Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of Voyager VI (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination With Cemiplimab in Patients With Select Solid Tumors

NCT04291105 is registered in ClinicalTrials.gov with Vyriad, Inc. as lead sponsor.

NCT NCT04291105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04291105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of Voyager VI (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination With Cemiplimab in Patients With Select Solid Tumors
Lead sponsor
Vyriad, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 24, 2020
Completion date
December 31, 2026
Enrollment
87 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

colo-rectal cancer, head and neck squamous cell carcinoma, melanoma